A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.
about
Combined surgical and molecular therapy: the gastrointestinal stromal tumor modelGenetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumorsSyndromic gastrointestinal stromal tumorsMyxoid epithelioid gastrointestinal stromal tumor harboring an unreported PDGFRA mutation: report of a case and review of the literatureCIViC databaseMolecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.KIT and PDGFRalpha mutational analyses of mixed cell-type gastrointestinal stromal tumours.P53 expression is significantly correlated with high risk of malignancy and epithelioid differentiation in GISTs. An immunohistochemical study of 104 cases.Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibitionPitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors.Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis.Targeted therapy for cancer: the gastrointestinal stromal tumor model.Gastrointestinal stromal tumors in a baboon, a spider monkey, and a chimpanzee and a review of the literatureNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region.A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)Is there something other than imatinib mesilate in therapeutic options for GIST?The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting.Histopathology of gastrointestinal stromal tumor.SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors.Gastrointestinal stromal tumor - an evolving concept.Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer.Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal TumorsAn update on molecular genetics of gastrointestinal stromal tumours.Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literatureCurrent clinical management of gastrointestinal stromal tumors.Presence of PDGFRA and DOG1 mutations in gastrointestinal stromal tumors among Chinese population.Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions.Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations.The role of genetic testing in soft tissue sarcoma.KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors : recommendations for patient selection, risk assessment, and molecular response monitoring.Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors.Clinical implications of mutational analysis in gastrointestinal stromal tumours.Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas.Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential.Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors
P2860
Q24675987-1770C2E1-4162-44C0-83F7-70BE3C1D07D6Q26738567-4F12D1F7-29D3-4705-8C17-ABADD328E9FDQ26738882-F4EB26EF-B5B3-468E-AB1C-7251DEDDB6A1Q26801942-E6FEE5BE-061E-4316-BD7C-E0C2BECB1A85Q27612411-63B0769A-5238-4599-A860-E3CF69E3E1BBQ30245586-90CAB831-3B5C-4879-8CAB-61F0CF5740E2Q33307442-AD9A6774-4537-466E-A6F5-784FF7356E90Q33354638-EE062888-4633-44AA-98B3-CDC06E4EC206Q33583469-A5965C1E-A697-4841-89BA-5CD1642980A5Q33624278-0913F096-D5E8-458F-84C1-8CDC0313355BQ33712862-49163BF4-192D-4ED0-A8A1-E5BF21E8846EQ33807742-D0B6687A-64B1-453E-BD59-E9208A01C31EQ33919552-0C21A377-E0B2-4F6C-8985-3D8E2D582B60Q33921067-8AD9A438-8307-4824-9701-D78954AF3CB9Q34005890-6A86876B-ADFD-49E9-8EE1-763E709B1334Q34036409-78D84010-FE23-4AD8-AC70-DD0234C00402Q34207379-B55845CE-B0E8-4254-8D78-552869BA1F17Q34629408-18D4125C-FF89-4FA3-9F24-BD07B92C1BECQ34633603-2684E06F-3BD5-4AEE-86F3-B5BEE891A4E0Q34729952-4213F994-E9CE-4688-AEF8-7F92EE28DC69Q34928165-8DE3C279-5AE7-4492-AAB9-5C3FC06A1B99Q35082777-FECB7389-8090-4510-9711-93EE5BDE7D3BQ35119141-0B59212A-7DFF-4666-B393-DE8F44DAA4CFQ35770066-6D61D91A-7827-4431-929A-C9B7B07225DAQ35789573-E4598CD8-9F26-4035-92A3-FD094CCDAEA0Q35834757-29AF38B2-0807-4C3A-B8D1-373D88293DDBQ35843690-9D96AF76-914A-4BB7-9E99-8D508439FD82Q35854357-4B573E88-216A-4B7C-A280-888B89186107Q35904105-36C3D651-C9C1-4010-AE15-B9662328335EQ35921190-1A398794-58B3-4CEE-871C-EAFD076E9CCBQ36344267-42471433-F6B1-4697-BECB-484634FB1DBDQ36536625-73320D82-5AB2-4E4F-B6B3-DCBFEA823946Q36589296-388BCC3F-A5FF-491A-B730-AF0141909E82Q36925163-6489438C-EB6E-4DBA-B20B-6C19DF7C423FQ37078090-39D59A4A-0BF8-4EBA-A813-964342F3CEA1Q37142082-448203FE-39D0-4A1B-8D3B-410252986AF0Q37147765-B8E472F4-74CA-4DD8-B32F-9C8D78CCC57CQ37176371-57CC3FEE-7679-4FDF-B1BF-A550E0175A6EQ37237696-CB115245-9301-4E47-A767-21D786599FE1Q37405941-4B04A9C5-F417-45A8-B305-1637EFE44D14
P2860
A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A great majority of GISTs with ...... low or no malignant potential.
@ast
A great majority of GISTs with ...... low or no malignant potential.
@en
A great majority of GISTs with ...... low or no malignant potential.
@nl
type
label
A great majority of GISTs with ...... low or no malignant potential.
@ast
A great majority of GISTs with ...... low or no malignant potential.
@en
A great majority of GISTs with ...... low or no malignant potential.
@nl
prefLabel
A great majority of GISTs with ...... low or no malignant potential.
@ast
A great majority of GISTs with ...... low or no malignant potential.
@en
A great majority of GISTs with ...... low or no malignant potential.
@nl
P2093
P2860
P3181
P1476
A great majority of GISTs with ...... low or no malignant potential.
@en
P2093
Jerzy Lasota
Leslie H Sobin
Markku Miettinen
P2860
P2888
P304
P3181
P356
10.1038/LABINVEST.3700122
P577
2004-07-01T00:00:00Z
P5875
P6179
1021134886